—
C+
C+ The full Closelook — membership. Open the C+ overview

Glaukos Corp (GKOS) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Glaukos Corp

GKOS in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Glaukos develops and sells devices and drug therapies for eye disease, with its core work centred on glaucoma. Its main products are the iStent and iStent infinite micro-bypass devices, which open natural drainage channels to relieve pressure inside the eye, alongside iDose TR, an implant that releases pressure-lowering medicine over time. It also makes iLink, a treatment for the corneal thinning condition keratoconus, and is building platforms aimed at retinal disease and skin-applied eye drug delivery. Its customers are surgery centres, hospitals and eye specialists, reached through its own sales staff and outside distributors. It is based in Aliso Viejo, California.
Where it sits in the stack
Glaukos holds no seat in Closelook's index. It sits in the diary's Healthcare sleeve, in the medical-devices group, among other US makers of surgical and implant-based eye therapies.
Who it is priced against
Closelook's peer group draws on scored Healthcare names based in the US, including Globus Medical, Veeva Systems, Regeneron Pharmaceuticals and Vertex Pharmaceuticals; the market's closer comparison is Alcon, the larger eye-care device maker.
Why Closelook tracks it
Glaukos carries a Closelook score, with momentum the strongest module and valuation the weakest; it has no index seat and has not yet drawn a diary quote.
What the diary watches
The diary watches whether the strong momentum reading holds as the shares sit off their recent high, and whether the weak valuation module narrows as analyst forecasts move.

Glaukos Corp (GKOS) trades on US exchanges.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for GKOS, from the same nightly bakes the boards use. Research diary readings, not advice.

The Street on this name 1 analyst action on the wire · latest: price target by BTIG, 2026-08-20

The Street on this name

Analyst actions and the latest print for GKOS from the Closelook wires — third-party opinions on the record, not our readings.

  • Price target BTIG — target 202 from 193 Target raised to $202 from $193 (+6.6% to spot) 2026-08-20

1 action on the analyst wire since 2026-08-13: 1 target change. Analyst wire → · Earnings wire →

Who it is priced against Medical Devices · US · 8 names with week and year-to-date

Peer group

Medical Devices · US

This name carries no Closelook score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against GKOS on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 50/100 · S&P 500 fund at 49, above its 50- and 200-day averagesEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-18
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 97th percentile of the window, +4.9% over 20 sessions. Factor regime → 2026-09-18
  • Sovereign pressure Index 0.07 · down 0.41 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-18

FAQ · from the current data · as of 2026-09-19

Quick answers

What is Glaukos Corp (GKOS)?

Glaukos Corp trades as GKOS on the US exchange (US) in the Closelook research universe, as of the registry build of 2026-09-19.

Is GKOS in a Closelook index?

Not currently — Glaukos Corp is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-19.

Where does GKOS trade against its moving averages?

Pullback inside an uptrend stack: Trades -4.2% vs the 50-day and +23.6% vs the 200-day average, 14.5% below the 52-week high and +123.9% off the 52-week low. Computed from daily closes. As of 2026-09-18 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Glaukos Corp do?

Glaukos develops and sells devices and drug therapies for eye disease, with its core work centred on glaucoma. Its main products are the iStent and iStent infinite micro-bypass devices, which open natural drainage channels to relieve pressure inside the eye, alongside iDose TR, an implant that releases pressure-lowering medicine over time. It also makes iLink, a treatment for the corneal thinning condition keratoconus, and is building platforms aimed at retinal disease and skin-applied eye drug delivery. Closelook's peer group draws on scored Healthcare names based in the US, including Globus Medical, Veeva Systems, Regeneron Pharmaceuticals and Vertex Pharmaceuticals; the market's closer comparison is Alcon, the larger eye-care device maker.

Where does Glaukos Corp sit in the AI build-out?

Glaukos holds no seat in Closelook's index. It sits in the diary's Healthcare sleeve, in the medical-devices group, among other US makers of surgical and implant-based eye therapies. Glaukos carries a Closelook score, with momentum the strongest module and valuation the weakest; it has no index seat and has not yet drawn a diary quote.

What has Wall Street done on Glaukos Corp recently?

The most recent analyst action on Glaukos Corp on the Closelook wire is a price target by BTIG on 2026-08-20 (target 202 from 193). 1 action on the analyst wire since 2026-08-13: 1 target change. Analyst actions are third-party opinions recorded by the wire, not Closelook readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for GKOS, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe

then Medical Devices. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.